GENESIS Ventures

Genesis Therapeutics is an AI-focused biotechnology company that leverages deep learning to accelerate the discovery of small molecule drugs for challenging targets. The company's proprietary GEMS platform integrates 3D structure-aware neural networks with molecular simulation to predict drug-target interactions with high precision. Genesis is advancing an internal pipeline of programs primarily focused on oncology and inflammatory diseases, while also maintaining strategic collaborations with major pharmaceutical companies like Genentech and Eli Lilly. Founded by pioneers in AI and molecular biology from Stanford University, the company is well-funded by leading investors to bridge the gap between computational innovation and clinical drug development.